Cargando…
Computational prediction of interactions between Paxlovid and prescription drugs
Pfizer’s Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as h...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
National Academy of Sciences
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041137/ https://www.ncbi.nlm.nih.gov/pubmed/36913586 http://dx.doi.org/10.1073/pnas.2221857120 |